vs
Side-by-side financial comparison of JOINT Corp (JYNT) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
SCYNEXIS INC is the larger business by last-quarter revenue ($18.6M vs $15.2M, roughly 1.2× JOINT Corp). SCYNEXIS INC runs the higher net margin — 65.7% vs 6.5%, a 59.2% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 3.1%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs -28.6%).
The Joint Corp is a leading operator and franchisor of chiropractic care clinics primarily serving the U.S. market. It offers accessible, affordable routine chiropractic services, membership-based care plans, and caters to consumers seeking non-invasive musculoskeletal pain management and wellness support.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
JYNT vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $15.2M | $18.6M |
| Net Profit | $991.1K | $12.3M |
| Gross Margin | 81.4% | — |
| Operating Margin | 4.9% | 56.3% |
| Net Margin | 6.5% | 65.7% |
| Revenue YoY | 3.1% | 1808.5% |
| Net Profit YoY | 5510.5% | 376.5% |
| EPS (diluted) | $0.06 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $15.2M | $18.6M | ||
| Q3 25 | $13.4M | $334.0K | ||
| Q2 25 | $13.3M | $1.4M | ||
| Q1 25 | $13.1M | $257.0K | ||
| Q4 24 | $14.7M | $977.0K | ||
| Q3 24 | $30.2M | $660.0K | ||
| Q2 24 | $30.3M | $736.0K | ||
| Q1 24 | $29.7M | $1.4M |
| Q4 25 | $991.1K | $12.3M | ||
| Q3 25 | $855.0K | $-8.6M | ||
| Q2 25 | $93.4K | $-6.9M | ||
| Q1 25 | $967.8K | $-5.4M | ||
| Q4 24 | $17.7K | — | ||
| Q3 24 | $-3.2M | $-2.8M | ||
| Q2 24 | $-3.6M | $-14.5M | ||
| Q1 24 | $947.0K | $411.0K |
| Q4 25 | 81.4% | — | ||
| Q3 25 | 80.1% | — | ||
| Q2 25 | 79.1% | — | ||
| Q1 25 | 77.3% | — | ||
| Q4 24 | 78.4% | — | ||
| Q3 24 | 90.7% | — | ||
| Q2 24 | 90.7% | — | ||
| Q1 24 | 90.9% | — |
| Q4 25 | 4.9% | 56.3% | ||
| Q3 25 | 1.2% | -2516.5% | ||
| Q2 25 | -8.6% | -701.0% | ||
| Q1 25 | -5.2% | -3350.2% | ||
| Q4 24 | 5.5% | — | ||
| Q3 24 | -1.6% | -1563.6% | ||
| Q2 24 | -5.9% | -1255.0% | ||
| Q1 24 | -1.4% | -692.5% |
| Q4 25 | 6.5% | 65.7% | ||
| Q3 25 | 6.4% | -2572.2% | ||
| Q2 25 | 0.7% | -504.8% | ||
| Q1 25 | 7.4% | -2097.7% | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | -10.5% | -425.5% | ||
| Q2 24 | -11.9% | -1964.4% | ||
| Q1 24 | 3.2% | 29.9% |
| Q4 25 | $0.06 | $0.25 | ||
| Q3 25 | $0.06 | $-0.17 | ||
| Q2 25 | $0.01 | $-0.14 | ||
| Q1 25 | $0.06 | $-0.11 | ||
| Q4 24 | $0.01 | — | ||
| Q3 24 | $-0.21 | $-0.06 | ||
| Q2 24 | $-0.24 | $-0.30 | ||
| Q1 24 | $0.06 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $23.6M | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $15.1M | $49.4M |
| Total Assets | $61.0M | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $23.6M | $40.0M | ||
| Q3 25 | $29.7M | $37.9M | ||
| Q2 25 | $29.8M | $44.8M | ||
| Q1 25 | $21.9M | $40.6M | ||
| Q4 24 | $25.1M | $59.3M | ||
| Q3 24 | $20.7M | $68.8M | ||
| Q2 24 | $17.5M | $73.0M | ||
| Q1 24 | $18.7M | $80.2M |
| Q4 25 | $15.1M | $49.4M | ||
| Q3 25 | $22.7M | $36.4M | ||
| Q2 25 | $23.2M | $44.5M | ||
| Q1 25 | $22.8M | $50.5M | ||
| Q4 24 | $20.7M | $55.1M | ||
| Q3 24 | $20.5M | $58.5M | ||
| Q2 24 | $23.2M | $60.4M | ||
| Q1 24 | $26.2M | $74.1M |
| Q4 25 | $61.0M | $59.0M | ||
| Q3 25 | $69.4M | $51.1M | ||
| Q2 25 | $73.2M | $60.7M | ||
| Q1 25 | $80.1M | $67.9M | ||
| Q4 24 | $83.2M | $90.6M | ||
| Q3 24 | $79.6M | $99.0M | ||
| Q2 24 | $82.4M | $107.8M | ||
| Q1 24 | $85.7M | $118.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.8M | $18.4M |
| Free Cash FlowOCF − Capex | $334.7K | — |
| FCF MarginFCF / Revenue | 2.2% | — |
| Capex IntensityCapex / Revenue | 9.9% | — |
| Cash ConversionOCF / Net Profit | 1.86× | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $-1.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.8M | $18.4M | ||
| Q3 25 | $1.8M | $-8.7M | ||
| Q2 25 | $868.6K | $-7.5M | ||
| Q1 25 | $-3.7M | $-7.5M | ||
| Q4 24 | $9.4M | $-24.0M | ||
| Q3 24 | $3.4M | $765.0K | ||
| Q2 24 | $-973.5K | $-10.9M | ||
| Q1 24 | $2.8M | $-4.0M |
| Q4 25 | $334.7K | — | ||
| Q3 25 | $1.5M | — | ||
| Q2 25 | $363.6K | — | ||
| Q1 25 | $-4.0M | — | ||
| Q4 24 | $8.2M | — | ||
| Q3 24 | $3.2M | — | ||
| Q2 24 | $-1.2M | — | ||
| Q1 24 | $2.4M | — |
| Q4 25 | 2.2% | — | ||
| Q3 25 | 10.9% | — | ||
| Q2 25 | 2.7% | — | ||
| Q1 25 | -30.8% | — | ||
| Q4 24 | 55.9% | — | ||
| Q3 24 | 10.6% | — | ||
| Q2 24 | -4.1% | — | ||
| Q1 24 | 8.1% | — |
| Q4 25 | 9.9% | — | ||
| Q3 25 | 2.4% | — | ||
| Q2 25 | 3.8% | — | ||
| Q1 25 | 2.5% | — | ||
| Q4 24 | 8.1% | — | ||
| Q3 24 | 0.8% | — | ||
| Q2 24 | 0.9% | — | ||
| Q1 24 | 1.3% | — |
| Q4 25 | 1.86× | 1.50× | ||
| Q3 25 | 2.07× | — | ||
| Q2 25 | 9.30× | — | ||
| Q1 25 | -3.82× | — | ||
| Q4 24 | 532.98× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 2.97× | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JYNT
| Transferred At Point In Time | $12.8M | 84% |
| Transferred Over Time | $2.4M | 16% |
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
